ADVAIR HFA Drug Patent Profile

When do Advair Hfa patents expire, and what generic alternatives are available?

Advair Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA.

The generic ingredient in ADVAIR HFA is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Advair Hfa

A generic version of ADVAIR HFA was approved as fluticasone propionate; salmeterol xinafoate by HIKMA on December 17^th, 2020.

Summary for ADVAIR HFA

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ADVAIR HFA

US Patents and Regulatory Information for ADVAIR HFA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-001	Jun 8, 2006		RX	Yes	Yes
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-002	Jun 8, 2006		RX	Yes	Yes
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-003	Jun 8, 2006		RX	Yes	Yes

International Patents for ADVAIR HFA

See the table below for patents covering ADVAIR HFA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2217954	INHALATEUR DOSEUR DE SALMETEROL (METERED DOSE INHALER FOR SALMETEROL)
Poland	189244
Australia	755977
Bulgaria	101972

Supplementary Protection Certificates for ADVAIR HFA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506844	18C1022	France		PRODUCT NAME: COMBINAISON COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (EN PARTICULIER LE BROMURE D'UMECLIDINIUM), DU VILANTEROL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (EN PARTICULIER LE TRIFENATATE DE VILANTEROL), ET DU FUROATE DE FLUTICASONE; REGISTRATION NO/DATE: EU/1/17/1236 20171117
2506844	LUC00077	Luxembourg		PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
2506844	SPC/GB18/020	United Kingdom		PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117
2506844	132018000000341	Italy		PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117

Investment Scenario, Market Dynamics, and Financial Trajectory for ADVAIR HFA

Last updated: February 3, 2026

Summary

Advair HFA (fluticasone propionate and salmeterol inhalation aerosol) is a leading prescription medication indicated for asthma and COPD management. Market shifts towards biosimilar competition, evolving regulatory landscapes, and patent expirations significantly influence its investment outlook. This report analyzes the current market dynamics, projected sales trajectory, competitive landscape, and regulatory challenges shaping the financial prospects for Advair HFA over the next five years.

Introduction: Overview of Advair HFA

Attribute	Details
Active Ingredients	Fluticasone propionate + Salmeterol
Approved Indication(s)	Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Market Launch	1990s (original formulation), HFA inhaler introduced 2009
Patent Status	Patent exclusivity concluded in key markets (e.g., US 2018, EU 2017)
Current Status	Blockbuster drug, with annual sales > $1.8 billion (pre-patent expiry)

Market Dynamics

1. Sales Trends and Market Size

Period	Global Sales (USD Billions)	Growth Rate (CAGR)	Notes
2015-2017	1.8	5-7%	Peak sales before patent expiry
2018 (Post-Patent)	1.2	-	Sales decline due to generic competition
2019-2022	1.3 - 1.6	2-4%	Market stabilization, biosimilar entries
2023-2028 (Forecast)	1.2 - 1.4	-1 to 2%	Impact of biosimilars, new treatments, consolidation

2. Patent Expiry Impact and Generic/Biosimilar Competition

Year	Patent Expiry	Market Response	Effects
2018	US, EU patents end	Entry of generic fluticasone + salmeterol	Significant share loss (~50-60%), revenue decline
2021-2023	Biosimilar approvals	Biosimilar inhalers gaining approval	Potential erosion of branded sales, increased price competition
2024-2028	Further biosimilar market penetration	Increased competition	Continuous pressure on margins, volume-based revenue shifts

3. Regulatory and Policy Environment

Factor	Impact	Details
Generic/Biosimilar Policies	Accelerated approvals, price pressures	Policies favor biosimilar adoption (e.g., US, EU)
Pricing Reforms	Reduced reimbursement rates	Governments seek cost savings, impacting revenues
Patent Laws	Patent challenges, extensions	Ongoing legal battles; delays in biosimilar launches

4. Market Drivers and Barriers

Drivers	Barriers
Growing prevalence of asthma and COPD	Patent litigation complexities
Enhanced inhaler devices and compliance tools	Stringent regulatory approval processes
Expanding global healthcare access	High R&D costs for biosimilars
Increasing age-related respiratory conditions	Price sensitivity in markets

5. Competitive Landscape

Entities	Market Share (Estimated)	Key Products	Notes
GSK (GlaxoSmithKline)	~50%	Advair HFA, Wixela (biosimilar)	Market leader, biosimilar challenger
Teva, Mylan, Sandoz	~20%	Multiple generic inhalers	Transition phase, increasing presence
Others (e.g., AstraZeneca, Novartis)	10-15%	New inhalers, alternative therapies	Innovation in delivery devices

Financial Trajectory

1. Pre-Patent Expiry Revenue

Year	Estimated Revenue	Notes
2016-2017	~$1.8 billion	Peak sales, strong market penetration
2018	~$1.2 billion	Revenue decline post-patent loss

2. Post-Patent Revenue Projections (2023-2028)

Scenario	Annual Revenue (USD Billions)	Key Assumptions	Implications
Conservative	~$1.2	Biosimilar penetration at 30%, moderate patent challenges	Steady decline, minimal recovery
Moderate Growth	~$1.3 - 1.4	Faster biosimilar adoption, lifecycle management	Slight recovery via new indications, improved market share
Aggressive Innovation	~$1.5+	Launch of new inhaler platforms, combination therapies	Market expansion, offsetting biosimilar competition

3. Cost and Profitability

Cost Components	Details
R&D for biosimilars/private label drugs	Significant, high regulatory hurdles
Manufacturing & Distribution	Economies of scale favored post-patent expiry
Marketing & Sales	Declining, targeted towards biosimilar strategies

Profit Margin Trends	Pre-Patent	Post-Patent	Forecast (2023-2028)
Gross Margin	~65-70%	55-60%	55-62%
Operating Margin	~40-45%	20-30%	25-35%

Comparison to Industry Benchmarks

Parameter	Advair HFA	Industry Average	Notes
Peak Sales (USD)	> $1.8 billion	N/A	Top-tier respiratory drug
Post-Patent Revenue Decline (%)	30-40%	N/A	Typical for blockbuster drugs post-expiry
Biosimilar Impact (% Market Share by 2025)	20-35%	Market-dependent	Significant but not complete erosion

Deep-Dive: Key Factors Influencing Future Performance

• Patent and Regulatory Landscape:
  Patent expiries in major markets and the advent of biosimilar inhalation therapies driving price reductions.

• Lifecycle Management Strategies:
  GSK’s deployment of reformulations, new delivery devices, and combination therapies to sustain revenue streams.

• Market Expansion:
  Growing COPD and asthma prevalence in Asia-Pacific and Latin America providing growth channels.

• Innovation and Technology:
  Advanced inhaler devices offering improved delivery and patient adherence could command premium pricing early on.

• Pricing and Reimbursement:
  Governments’ push for cost-effective treatments constrains pricing, pushing companies toward volume-based models.

FAQs

1. What is the expected impact of biosimilar inhalers on Advair HFA’s sales over the next five years?

Biosimilar inhalers are projected to capture approximately 20-35% of the global inhaler market by 2025, exerting significant pressure on Advair’s revenues, especially in Europe and North America where biosimilar adoption is more advanced.

2. How are competitors positioned relative to Advair HFA?

Leading generic manufacturers like Teva, Mylan, and Sandoz are expanding their portfolios with biosimilar and generic inhalers. GSK is focusing on lifecycle management and new formulations, but faces increased competition from these entrants.

3. Will Advair HFA’s revenue recover post-patent expiry?

Recovery depends on successful lifecycle management, new indications, and non-patent-driven revenue sources. However, significant erosion is expected unless GSK innovates or introduces new high-margin products.

4. How do regulatory policies affect Advair HFA’s future?

Stringent regulatory pathways for biosimilars and patent challenges increase market uncertainty. Favorable policies can accelerate biosimilar adoption, pressing branded drugs to innovate or consolidate.

5. What strategic moves should investors monitor?

Focus on GSK's pipeline development, lifecycle management efforts, biosimilar market penetration, emerging markets expansion, and regulatory landscape changes.

Key Takeaways

• Advair HFA's blockbuster status has been challenged since patent expiry in 2018, leading to a marked decline in revenues.
• Market consolidation and biosimilar competition are expected to erode sales further, with estimates of a 20-35% biosimilar market share by 2025.
• Innovation in inhaler technology, strategic lifecycle management, and foreign market expansion are vital for sustaining profitability.
• Regulatory policies and patent litigations remain significant uncertainties impacting future revenue streams.
• Investors should weigh the decline in branded revenues against the potential growth in biosimilar markets and pipeline innovations.

References

[1] GSK Annual Reports and Financial Statements, 2015-2022
[2] IQVIA Data on Respiratory Drug Sales, 2022
[3] US FDA Biosimilar Approvals, 2022
[4] EMA Market Access Reports, 2022
[5] Industry Analysis: Biosimilars in Respiratory Therapy, 2022